By Fineline Cube ACROBiosystems Group (SHE: 301080) has announced a partnership with China-based gene therapy specialist OBiO Technology (Shanghai) Co, Ltd (SHA: 688238). This collaboration aims to leverage the advantageous resources of both companies, enhancing their capabilities in cell and gene therapy (CGT) and expanding their global reach.
Resource integration and application in Cell and Gene Therapy
The partnership will see ACROBiosystems providing OBiO with its recombinant protein and GMP grade cytokines for the production and clinical development of biological agents. Additionally, ACROBiosystems’ nucleic acid tool enzymes and residue detection kits will be utilized to address nucleic acid residues in the production stage of OBiO’s biological agents. This collaboration not only strengthens OBiO’s production capabilities but also supports the quality and safety of their gene therapy offerings.
Global Promotion and Sales Support
ACROBiosystems will also assist OBiO in promoting and selling its neural research tool viruses and scientific research services on a global scale. This support will help OBiO expand its international presence and reach a wider customer base, enhancing its position as a provider of CRO and CDMO services in the gene therapy sector.
Background of ACROBiosystems and OBiO Technology
Founded in 2010, ACROBiosystems is a global biotechnology company dedicated to being a cornerstone of the biopharmaceutical and health industries through product and business model innovation. With a presence in 12 different cities across the United States, Switzerland, England, and Germany, ACROBiosystems has established long-term partnerships with top pharmaceutical companies such as Pfizer, Novartis, and Johnson & Johnson, as well as numerous renowned academic institutes.
OBiO, established in 2013, specializes in providing CRO services for gene therapy vector development and gene function research, and CDMO services including process development, testing, IND-CMC pharmaceutical research, and clinical sample GMP production for recombinant virus carrier drugs, oncolytic viruses, and CAR-T cell therapies.-Fineline Info & Tech